Travoprost eye drops

Mechanism of Action - Travoprost free acid is a selective FP prostate receptor agonist. It is reported that FP prostate receptor agonists can reduce intraocular pressure by increasing the outflow of aqueous humor through the uveoscleral pathway. Its exact mechanism of action is still unclear. Carcinogenicity, mutagenesis, and impairment of fertility No mutagenic effects were found in a two-year carcinogenicity study in rats and mice given subcutaneously at 10, 30 or 100ug/kg/day. However, at a dose of 100ug/kg/day, male rats were only treated for 82 weeks, and the maximum tolerated dose (MTD) was shown to be reached in mouse studies. Based on the effective drug amount in plasma, the high dose (100ug/kg) is equivalent to more than 400 times the exposure of the recommended maximum dose (MRHOD) of 0.04ug/kg for human eyes. Travoprost was not found to be mutagenic in the Ames test, the mouse micronucleus test, and the rat chromosome aberration test. In another mouse lymphoma study (one of two), high concentrations of travoprost were only slightly mutagenic in the presence of active rat S-9 enzyme. Travoprost was administered subcutaneously to male and female rats and mice at doses up to 10 μg/kg/day (250 times the maximum recommended dose for human ophthalmic use) without affecting mating or fertility indices. At this dose, the mean number of corpora lutea was reduced and post-implantation failure increased. However, there was no change in the number of corpora lutea at 3 μg/kg/day (75 times the maximum recommended dose for human ophthalmic use).

Chemical name: Isopropyl (z)-7-[(1R, 2R, 3R, 5S)-3,5-dihydroxy-2-[(1E, 3R)-3-hydroxy-4-[(a, a, a, -trifluoro-m-methylpropyl)oxy]-1-butenyl]cyclopentyl]-5-heptenoic acid Molecular weight: C26H35F3O6

This product is a colorless to light yellow clear liquid.

No data yet

The recommended dosage is 1 drop per night into the affected eye. The dosage should not exceed 1 time per day, because frequent use will reduce the intraocular pressure lowering effect of the drug. The intraocular pressure lowering effect of Suweitan begins to appear about 2 hours after medication and reaches its maximum at 12 hours. Suweitan can be used together with other topical eye medications to lower intraocular pressure. When using more than one eye drop at the same time, the time between drops of each drug should be at least 5 minutes apart.

In controlled clinical studies of Suweitan, the most common ocular adverse reaction observed was ocular hyperemia, which occurred in 35%-50% of patients. Approximately 3% of patients discontinued medication due to conjunctival hyperemia. 5-10% of ocular adverse reactions included decreased vision, ocular discomfort, foreign body sensation, pain, and itching. 1-4% of ocular adverse reactions included abnormal vision, blepharitis, blurred vision, cataracts, inflammatory cells, conjunctivitis, dry eyes, ocular discomfort, atrial flare, heterochromia iris, keratitis, eyelid crusting, photophobia, subconjunctival hemorrhage, and tearing. Non-ocular adverse reactions accounted for 1~5%, including trauma, angina pectoris, anxiety, arthritis, back pain, bradycardia, tracheitis, chest pain, cold syndrome, depression, indigestion, gastrointestinal dysfunction, headache, hypercholesterolemia, hypertension, hypotension,

This drug is contraindicated in patients with hypersensitivity to travoprost, polyquaternium-1, or any of the ingredients in this drug.

Precautions for children: Safety and efficacy in children have not been studied. Precautions for pregnancy and lactation: Subcutaneous administration of travoprost at a dose of ≥0.12ug/kg/day (3 times the maximum recommended dose for human eye use) to female rat offspring from day 7 of pregnancy to day 21 of lactation increases postnatal mortality and reduces neonatal weight. It also affects neonatal growth, manifested as delayed eye opening, separation of the auricles and foreskin, and decreased movement. Adequate and well-controlled studies have not yet been conducted in pregnant women. This product can only be used during pregnancy if it has been shown to be beneficial to the fetus. Studies in lactating rats have shown that radioactive isotope-labeled travoprost and/or its metabolites are secreted into breast milk. It is unclear whether this drug or its metabolites are secreted into human milk. Because many drugs are secreted into breast milk, special precautions should be taken when using this product in lactating women. Precautions for the elderly: There is no significant difference in efficacy and adverse reactions between elderly patients and adult patients overall.

Drug interactions may occur if used with other drugs. Please consult your doctor or pharmacist for details.

Keep away from light and store in sealed container.

2.5ml: 0.1mg

24 months